Shareholder update

May 30, 2025 biodexa pharmaceuticals plc shareholder update biodexa pharmaceuticals plc (“biodexa” or the “company”) (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced a brief update for shareholders. financial position as of may 29, 2025, the company had access to the following cash resources:     $ millions cash at bank   5.7 cash in escrow for erapa phase 3 program   4.4     10.1       undrawn cprit grant for erapa phase 3 program   11.9       debt   0.5 the cprit grant, together with company match means the erapa phase 3 program is substantially funded.
BDRX Ratings Summary
BDRX Quant Ranking